Differentiation of solid-pseudopapillary tumors of the pancreas from pancreatic neuroendocrine tumors by using endoscopic ultrasound

2020 ◽  
Vol 44 (6) ◽  
pp. 947-953 ◽  
Author(s):  
Yuan Liu ◽  
Si Shi ◽  
Jie Hua ◽  
Jin Xu ◽  
Bo Zhang ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Endoscopic Ultrasound ◽  
Pancreatic Neuroendocrine Tumors ◽  
Solid Pseudopapillary Tumors

scholarly journals Endoscopic Ultrasound-Guided Radiofrequency Ablation: A New Therapeutic Approach for Pancreatic Neuroendocrine Tumors

2019 ◽  
Vol 104 (7) ◽  
pp. 2637-2647 ◽  
Author(s):  
Kira Oleinikov ◽  
Alain Dancour ◽  
Julia Epshtein ◽  
Ariel Benson ◽  
Haggi Mazeh ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Neuroendocrine Tumors ◽  
Endoscopic Ultrasound ◽  
Therapeutic Approach ◽  
Pancreatic Neuroendocrine Tumors ◽  
Ultrasound Guided

Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study

Endoscopy ◽  
2019 ◽  
Vol 51 (09) ◽  
pp. 836-842 ◽  
Author(s):  
Marc Barthet ◽  
Marc Giovannini ◽  
Nathalie Lesavre ◽  
Christian Boustiere ◽  
Bertrand Napoleon ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Neuroendocrine Tumors ◽  
Endoscopic Ultrasound ◽  
Multicenter Study ◽  
Cystic Neoplasm ◽  
Pancreatic Neuroendocrine Tumors ◽  
Prospective Multicenter Study ◽  
End Point ◽  
Mean Size

Abstract Background Pancreatic neuroendocrine tumors (NETs) and intraductal pancreatic mucinous neoplasia (IPMN) with worrisome features are surgically managed. Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) has recently been developed. The safety of EUS-RFA was the primary end point of this study, its efficacy the secondary end point. Methods This was a prospective multicenter study that was planned to include 30 patients with a 1-year follow-up with either a NET < 2 cm or a pancreatic cystic neoplasm (PCN), either a branch duct IPMN with worrisome features or a mucinous cystadenoma (MCA). EUS-RFA was performed with an 18G RFA cooling needle. Results 12 patients had 14 NETs (mean size 13.1 mm, range 10 – 20 mm); 17 patients had cystic tumors (16 IPMNs, 1 MCA; mean size 28 mm, range 9 – 60 mm). Overall three adverse events occurred (10 %), two of these in the first two patients (one pancreatitis, one small-bowel perforation). After these initial patients, modifications in the protocol resulted in a decrease in complications (3.5 %), with one patient having a pancreatic ductal stenosis. Among the 14 NETs, at 1-year follow-up 12 had completely disappeared (86 % tumor resolution), with three patients having a delayed response. Among the 17 PCNs, at 12 months, there were 11 complete disappearances and one diameter that decreased by > 50 % (significant response rate 71 %). All 12 mural nodules showed complete resolution. Conclusions EUS-RFA of pancreatic NETs or PCNs is safe with a 10 % complication rate, which can be decreased by improved prophylaxis for the procedure.

Su1376 Evaluation of the Shark Coreâ® Needle for Endoscopic Ultrasound-Guided Fine Needle Aspirations of Pancreatic Neuroendocrine Tumors

2017 ◽  
Vol 85 (5) ◽  
pp. AB356
Author(s):  
Benjamin Witt ◽  
Rachel Factor ◽  
Barbara Chadwick ◽  
Justin E. Caron ◽  
Ali Siddiqui ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Endoscopic Ultrasound ◽  
Pancreatic Neuroendocrine Tumors ◽  
Ultrasound Guided ◽  
Fine Needle
Sign in / Sign up

Export Citation Format

Share Document